眼下正值 2025 上半年财报季。日前,各大跨国药企已纷纷披露了其 H1 成绩单。与 2024 年年度排名相比,营收前三甲依然是强生、罗氏、默沙东。第 4-8 名的几家企业,营收相差不大。GLP-1 双雄排名均有提升:礼来凭借现象级产品替尔泊肽,营收同比大涨 41%,排名由去年的第 9 跃升至第 6;诺和诺德依靠司美格鲁肽的亮眼表现,超过赛诺菲,跻进了前十榜单。虽然替尔泊肽上半年收入低于司美格鲁肽...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.